摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)ethyl methanesulfonate | 376636-17-8

中文名称
——
中文别名
——
英文名称
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)ethyl methanesulfonate
英文别名
methanesulfonic acid 2-(2-tert-butoxycarbonylamino-thiazol-4-yl)-ethyl ester;2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-4-yl]ethyl methanesulfonate
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)ethyl methanesulfonate化学式
CAS
376636-17-8
化学式
C11H18N2O5S2
mdl
——
分子量
322.406
InChiKey
VGSLQZVFWSOFEP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.355±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    20
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    131
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
    申请人:Ryono Denis E.
    公开号:US20080009465A1
    公开(公告)日:2008-01-10
    Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
    提供了磷酸酯和磷酸酯激活剂,因此在治疗糖尿病和相关疾病方面非常有用,并具有以下结构: 其中 是杂环芳基环; R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ; R 5 和R 6 分别选择自H、烷基和卤素; Y为R 7 (CH 2 ) s 或不存在;以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义;或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
  • 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION
    申请人:Mookhtiar Kasim A.
    公开号:US20100144772A1
    公开(公告)日:2010-06-10
    Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.
    本公开涉及的化合物是式(I)的2,2,2-三取代乙酰胺衍生物,其多晶形态、立体异构体、前药、溶剂化物、药学上可接受的盐和制剂,可用作葡萄糖激酶激活剂。公开还描述了它们的制备过程。公开还描述了表征部分葡萄糖激酶激活剂的方法。
  • 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
    申请人:Mookhtiar Kasim A.
    公开号:US08940900B2
    公开(公告)日:2015-01-27
    Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.
    本公开涉及的化合物是式(I)的2,2,2-三取代乙酰胺衍生物,其多晶形态、立体异构体、前药、溶剂化物、药学上可接受的盐和制剂,可用作葡萄糖激酶激活剂。本公开还描述了它们的制备方法。本公开还描述了表征部分葡萄糖激酶激活剂的方法。
  • QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
    申请人:Principia Biopharma, Inc.
    公开号:US20160130268A1
    公开(公告)日:2016-05-12
    Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    公开了一种纤维母细胞生长因子抑制剂(FGFR)化合物,因此对于通过抑制FGFR可治疗的疾病具有用处。还公开了含有这种化合物的药物组合物和制备这种化合物的过程。
  • PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
    申请人:Principia Biopharma Inc.
    公开号:EP2994470B1
    公开(公告)日:2018-04-18
查看更多